Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Fundacion Rioja Salud, |
RCV000490768 | SCV000297726 | pathogenic | Rubinstein-Taybi syndrome 2 | 2016-07-01 | criteria provided, single submitter | research | |
Gene |
RCV000369937 | SCV000330598 | pathogenic | not provided | 2018-10-23 | criteria provided, single submitter | clinical testing | The R1055X variant in the EP300 gene has been reported previously in an individual with RTS; however parental segregation studies were not performed (Lopez et al., 2018). The The R1055X variant has been observed as a de novo variant with confirmed parentage in multiple patients with neurodevelopmental disorders previously tested at GeneDx. This variant is predicted to cause loss of normal protein function either through protein truncation or nonsense-mediated mRNA decay. The R1055X variant is not observed in large population cohorts (Lek et al., 2016). We interpret R1055X as a pathogenic variant. |
Genomic Medicine Lab, |
RCV000490768 | SCV001167575 | pathogenic | Rubinstein-Taybi syndrome 2 | 2018-05-24 | criteria provided, single submitter | clinical testing |